ES2174081T3 - Uso de n-(pirrol-1-il)piridinaminas sustituidas y no sustituidas como agentes anticonvulsivos. - Google Patents

Uso de n-(pirrol-1-il)piridinaminas sustituidas y no sustituidas como agentes anticonvulsivos.

Info

Publication number
ES2174081T3
ES2174081T3 ES96923693T ES96923693T ES2174081T3 ES 2174081 T3 ES2174081 T3 ES 2174081T3 ES 96923693 T ES96923693 T ES 96923693T ES 96923693 T ES96923693 T ES 96923693T ES 2174081 T3 ES2174081 T3 ES 2174081T3
Authority
ES
Spain
Prior art keywords
replaced
piridinamins
pirrol
anticonvulsive agents
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96923693T
Other languages
English (en)
Inventor
Francis P Huger
Sathapana Kongsamut
Craig P Smith
Lei Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2174081T3 publication Critical patent/ES2174081T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION ESTA RELACIONADA CON UN METODO DE TRATAMIENTO ANTICONVULSIVANTE QUE CONSISTE EN LA ADMINISTRACION DE UNA CANTIDAD EFICAZ DE LA FORMULA (I) DONDE R, R SUP,1}, R SUP,2}, R SUP,3}, R SUP,4}, M Y N SON COMO SE DEFINE EN EL INTERIOR.
ES96923693T 1995-07-27 1996-07-08 Uso de n-(pirrol-1-il)piridinaminas sustituidas y no sustituidas como agentes anticonvulsivos. Expired - Lifetime ES2174081T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50807195A 1995-07-27 1995-07-27

Publications (1)

Publication Number Publication Date
ES2174081T3 true ES2174081T3 (es) 2002-11-01

Family

ID=24021262

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96923693T Expired - Lifetime ES2174081T3 (es) 1995-07-27 1996-07-08 Uso de n-(pirrol-1-il)piridinaminas sustituidas y no sustituidas como agentes anticonvulsivos.

Country Status (20)

Country Link
EP (1) EP0840609B1 (es)
JP (1) JP4189029B2 (es)
KR (1) KR100445629B1 (es)
CN (1) CN1184969C (es)
AR (1) AR003471A1 (es)
AT (1) ATE218343T1 (es)
AU (1) AU696007B2 (es)
CA (1) CA2225156C (es)
DE (1) DE69621617T2 (es)
DK (1) DK0840609T3 (es)
ES (1) ES2174081T3 (es)
HK (1) HK1015687A1 (es)
IL (1) IL122845A0 (es)
MX (1) MX9800774A (es)
NO (1) NO315148B1 (es)
NZ (1) NZ312577A (es)
PT (1) PT840609E (es)
TW (1) TW464497B (es)
WO (1) WO1997004777A1 (es)
ZA (1) ZA966254B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
FR2897614B1 (fr) * 2006-02-20 2008-05-23 Urogene Forme cristalline du chlorhydrate de la besipirdine, procedes de preparation et utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032599A (en) * 1986-11-12 1991-07-16 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-l-yl)pyridinamines
EP0287982B1 (en) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments
US4868190A (en) * 1988-12-27 1989-09-19 Hoechst-Roussel Pharmaceuticals, Inc. N-pyridinyl-9H-carbazol-9-amines
US5179099A (en) * 1989-08-02 1993-01-12 Hoechst-Roussel Pharmaceuticals Incorporated 2,3-dihydro-1-(pyridinylamino)-indoles
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder

Also Published As

Publication number Publication date
DE69621617T2 (de) 2003-01-02
DK0840609T3 (da) 2002-09-30
MX9800774A (es) 1998-04-30
HK1015687A1 (en) 1999-10-22
AU696007B2 (en) 1998-08-27
KR100445629B1 (ko) 2004-10-14
DE69621617D1 (de) 2002-07-11
CN1191486A (zh) 1998-08-26
ZA966254B (en) 1997-02-11
JP4189029B2 (ja) 2008-12-03
NO980334L (no) 1998-03-26
EP0840609B1 (en) 2002-06-05
NO315148B1 (no) 2003-07-21
AR003471A1 (es) 1998-08-05
PT840609E (pt) 2002-10-31
ATE218343T1 (de) 2002-06-15
TW464497B (en) 2001-11-21
KR19990035973A (ko) 1999-05-25
AU6454796A (en) 1997-02-26
NZ312577A (en) 1999-08-30
WO1997004777A1 (en) 1997-02-13
EP0840609A1 (en) 1998-05-13
CN1184969C (zh) 2005-01-19
IL122845A0 (en) 1998-08-16
CA2225156C (en) 2003-06-10
NO980334D0 (no) 1998-01-26
CA2225156A1 (en) 1997-02-13
JPH11510159A (ja) 1999-09-07

Similar Documents

Publication Publication Date Title
PT797439E (pt) Utilizacao de pramipexote como agente neuroprotector
ES2179273T3 (es) N-bencil-2-fenilindolas como agentes estrogenicos.
IT1254517B (it) 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico
BG104247A (en) Resorcinol derivatives
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
HN1996000017A (es) Isotiazolonas
ES2124668B1 (es) "nuevosl-arilpirazoles con propiedades plaguicidas.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CR9879A (es) Moduladores de ccr5 (divisional de la solicitud n° 6392)
ES2161220T3 (es) 9-((glicil sustituido)amido)-6-desmetil-6-desoxitetraciclinas como agentes antibioticos.
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
ES2162951T3 (es) Estabilizacion de composiciones de prostaglandina.
DE59709414D1 (de) Oxyiminopregnancarbolactone
ES2163538T3 (es) Derivados de 3-oxo y 3-tioxo-4-aza-androstano diastereomericamente puros y su uso como antiandrogenos.
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ES2142512T3 (es) Nuevas substancias odoriferas.
MX9601994A (es) Profarmacos de derivados de paclitaxel.
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
AR004474A1 (es) Compuestos de 10-aminoalifatil-dibenz [b,f]oxepinas antineurodegenerativamente activas, utiles para el tratamiento de estados neurodegenerativos y composiciones farmaceuticas que los contienen
ES2192610T3 (es) Aminouracilos substituidos.
ES2061811T3 (es) Uso de compuestos de gamma-oxibutenolido conjugados para tratar ulcera.
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 840609

Country of ref document: ES